

Priliximab Biosimilar - Research Grade

Product Code: ICH5788

More Information

Species Reactivity: Human

Target: CD4 α 1/2

Concentration: 5mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Priliximab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P01730

Shipping Conditions: Blue ice

background: CD4 is the defining co-receptor of helper T cells and a foundational target in immunology and HIV research. This recombinant human IgG1 kappa antibody is an unconjugated, non-therapeutic analog of priliximab, produced in CHO cells against human CD4. Released for research use only, it is formulated to low endotoxin for in vivo suitability and manufactured in scalable milligram (mg) to gram (g) quantities for high-throughput laboratories. It serves as a dependable reagent for T-cell phenotyping, receptor-blockade and functional assays, in vivo immunology models, and antibody-engineering workflows. Consistent lot-to-lot performance makes it dependable for repeated, large-scale experimentation.

Other names: CD4, CD4mut, CD4 molecule, OKT4D, IMD79

Purification Method: This monoclonal antibody was purified using Protein A



Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks